Table 1.
A summary of multifunctional PVNPs for cancer immunotherapies
Immunotherapies functions | PVNP | Delivery agents | Tumor candidate | Function and major effect | Ref |
---|---|---|---|---|---|
Vaccine delivery | PVX | HPV-E7 antigen | Cervical cancers | Induce a humoral and cell immune response | [59, 60] |
PVX, CPMV, CCMV, SeMV, TMV | HER2 epitopes | Breast cancer | Production of HER2-specific antibodies in mice | [34, 58, 61, 62] | |
CPMV | NYESO-1157–165 | NY-ESO 1+malignancies | Uptake and activation of antigen presenting cells and stimulated a potent CD8+T cell response in transgenic human HLA-A2 expressing mice | [63] | |
PVX | Idiotypic (Id) | B-cell lymphoma | Induction of strong antibody response | [64] | |
TMV | Peptide p15 | Melanoma | Improve the survival in mouse model | [43] | |
Adjuvant delivery | CCMV | CpG | Colon cancer and Melanoma | Enhances the efficacy of CpG, slowing tumor growth in mouse models | [65] |
Monotherapy | CPMV, TMV, PVX, AMV | No antigen | Melanoma, Breast, Glioma and Ovarian cancer | Anti tumor activity by innate and adaptive immune responses | [29, 35, 38, 45, 53, 66] [29][67] [68] |